Showing results (41-50 of 216) with videos related to

Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|July 15, 2015
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapyShintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancerIkuo Sekine, Minako Sumi, Yoshinori Ito, et al.
Respiratory Investigation|January 1, 2022
Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancerAkiko Tateishi, Hidehito Horinouchi, Tatsuya Yoshida, et al.
Respiratory Investigation|September 11, 2022
Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series studyYoshitaka Seki, Tatsuya Yoshida, Takashi Kohno, et al.
Lung Cancer (Amsterdam, Netherlands)|September 9, 2025
Identification of poor prognostic factors using circulating extracellular vesicles in durvalumab consolidation therapy for locally advanced non-small cell lung cancerHirofumi Utsumi, Shigehiro Yagishita, Kazuki Kawajiri, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2025
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapiesHironori Satoh, Yusuke Okuma, Yuki Shinno, et al.
JTO Clinical and Research Reports|February 16, 2024
Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR MutationsYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.
Cancer Science|September 11, 2019
Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancerYoshinori Makino, Reiko Makihara-Ando, Takanori Ogawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancerYuko Minami-Shimmyo, Yuichiro Ohe, Seiichiro Yamamoto, et al.
Clinical Lung Cancer|January 25, 2014
Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analysesTomoko Katsui Taniyama, Hiroshi Nokihara, Koji Tsuta, et al.
Pageof 22